What makes peptides so valuable is how they support your body during this messy repair process
Ongoing support to help you maximize results and stay motivated

Evidence-Supported Indications Adults with BMI 35 kg/m, or BMI 27 with at least one or more weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea Type 2 Diabetes: Adults requiring improved glycemic control this remains the foundation of the drug class and where the longest safety record exists Cardiovascular Risk Reduction: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease Metabolic Syndrome Presentations: Patients with non-alcoholic fatty liver disease, polycystic ovarian syndrome, and insulin resistance syndromes Binge Eating Disorder (BED) Emerging Data: Emerging evidence suggests GLP-1 medications may reduce binge frequency though this data remains preliminary and is discussed in detail below Why It Is Not "Cheating" The genetics of obesity are increasingly well-characterized

Semaglutide Risks and Long-Term Safety Questions Despite its benefits, semaglutide risks must be carefully weighed, especially for long-term use
However further clinical studies are required to ascertain the benefit of semaglutide for alcoholics
Article written by: Doris Munoz-Mantilla, MD, FOMA, DABOM Article reviewed by: Anila Chadha MD, DABOM Family physician and Obesity Medicine physician at Dignity Health Medical Group, Bakersfield, California